common
cold
viral
airway
infect
highli
preval
popul
treatment
often
requir
use
medic
symptomat
relief
paracetamol
analges
antipyret
chlorphenamin
antihistamin
phenylephrin
vasoconstrictor
decongest
random
doubleblind
placebocontrol
trial
sought
evalu
efficaci
safeti
fixeddos
combin
paracetamol
chlorphenamin
phenylephrin
symptomat
treatment
common
cold
flulik
syndrom
adult
method
studi
enrol
individu
age
year
moder
sever
flulik
syndrom
common
cold
clinic
examin
laboratori
test
individu
randomli
assign
receiv
fixeddos
combin
placebo
five
capsul
per
day
hour
primari
efficaci
endpoint
sum
score
symptom
fourpoint
likerttyp
scale
evalu
treatment
safeti
occurr
advers
event
also
measur
result
mean
age
year
placebo
group
treatment
group
women
men
placebo
group
women
men
treatment
group
comparison
overal
symptom
score
two
group
reveal
significantli
greater
reduct
treatment
group
placebo
group
p
analysi
first
dose
interv
h
treatment
show
greater
reduct
symptom
score
treatment
group
placebo
group
p
number
distribut
advers
event
similar
group
conclus
fixeddos
combin
paracetamol
chlorphenamin
phenylephrin
safe
effect
placebo
symptomat
treatment
common
cold
flulik
syndrom
adult
trial
registr
acut
respiratori
infect
highli
preval
popul
common
cold
flulik
syndrom
tracheobronch
sinus
laryng
pneumonia
particularli
import
aetiolog
presum
bacteri
treatment
base
use
antibiot
medic
symptomat
relief
howev
common
clinic
entiti
common
cold
flulik
syndrom
viral
aetiolog
symptomat
treatment
remain
case
standard
recommend
common
cold
frequent
encount
diseas
medic
practic
affect
adult
averag
two
four
time
year
account
work
absenc
among
econom
activ
popul
unit
state
syndrom
affect
upper
airway
sometim
associ
lowgrad
fever
system
symptom
usual
present
least
two
follow
symptom
cough
dysphonia
throat
discomfort
sore
throat
nasal
congest
rhinorrhoea
sneez
headach
myalgia
fever
symptom
usual
peak
day
mean
durat
day
definit
prospect
valid
studi
frequent
use
clinic
studi
patient
common
cold
although
case
caus
rhinoviru
agent
may
involv
respiratori
syncyti
viru
adenoviru
coronaviru
influenza
parainfluenza
virus
flulik
syndrom
character
sudden
onset
fever
headach
cough
sore
throat
myalgia
nasal
congest
weak
loss
appetit
complic
pneumonia
otiti
sinus
may
occur
medic
studi
treatment
common
cold
antihistamin
anticholinerg
alphaadrenerg
agonist
membran
stabil
nonsteroid
antiinflammatori
drug
vitamin
c
glucocorticoid
zinc
herbal
medic
alphainterferon
clinic
trial
highdos
vitamin
c
found
benefit
treatment
common
cold
recent
studi
echinacea
purpurea
herbal
medicin
find
clinic
benefit
patient
common
cold
result
metaanalys
efficaci
zinc
contradictori
weak
evid
benefit
welldesign
studi
symptomat
treatment
common
cold
evalu
cochran
metaanalys
first
includ
studi
total
patient
investig
administr
antihistamin
common
cold
result
show
monotherapi
improv
symptom
either
children
adult
combin
use
antihistamin
decongest
may
allevi
symptom
adult
result
heterogen
anoth
metaanalysi
investig
use
nasal
decongest
common
cold
adult
found
benefit
relief
nasal
congest
anoth
recent
metaanalysi
suggest
tripl
combin
antihistamin
decongest
analges
provid
gener
benefit
adult
older
children
case
influenza
requir
use
drug
symptomat
relief
clinic
practic
treatment
direct
aetiolog
agent
routin
becam
consider
frequent
pandem
therefor
patient
continu
use
medic
produc
symptomat
relief
epidemiolog
relev
intens
symptom
flulik
syndrom
common
cold
studi
evalu
efficaci
safeti
fixeddos
combin
paracetamol
chlorphenamin
phenylephrin
symptomat
treatment
common
cold
flulik
syndrom
analys
symptom
score
reduct
treatment
durat
symptom
return
usual
activ
advers
event
group
random
clinic
trial
rct
evalu
safeti
efficaci
specif
fixeddos
combin
common
cold
adult
first
rct
conduct
brazil
design
also
assess
advers
cardiovascular
effect
phenylephrin
phase
iii
prospect
random
doubleblind
placebocontrol
clinic
trial
enrol
volunt
recruit
mean
poster
display
hospit
de
de
porto
alegr
hcpa
primari
care
centr
citi
porto
alegr
brazil
ad
place
local
newspap
studi
includ
volunt
gender
age
year
durat
symptom
longer
hour
common
cold
defin
presenc
least
two
follow
symptom
sneez
rhinorrhoea
nasal
congest
headach
myalgia
throat
discomfort
sore
throat
dysphonia
cough
fever
symptom
moder
sever
fourpoint
likerttyp
symptom
sever
scale
symptom
mild
moder
sever
flulik
syndrom
includ
fever
least
moder
sever
headach
moder
sever
myalgia
arthralgia
likerttyp
symptom
sever
scale
describ
volunt
exclud
studi
met
follow
criteria
pregnanc
breastfeed
known
hypersensit
compon
studi
formul
use
alcohol
illicit
drug
use
monoamin
oxidas
mao
inhibitor
barbitur
perenni
season
allerg
rhiniti
confirm
screen
current
acut
diseas
uncontrol
exacerb
chronic
diseas
clinic
evid
immunosuppress
vaccin
influenza
week
inclus
need
antivir
therapi
treat
influenza
b
infect
need
antibacteri
therapi
treat
acut
respiratori
infect
use
medic
treat
condit
acquir
inclus
time
shorter
two
time
interv
administr
drug
particip
anoth
clinic
trial
less
year
statist
power
random
error
respons
rate
treatment
group
comparison
placebo
group
reduct
symptom
score
second
day
followup
placebo
group
sampl
size
calcul
patient
group
account
possibl
loss
followup
volunt
patient
includ
studi
group
variabl
collect
enter
databas
random
code
open
databas
creat
use
epiinfo
softwar
spss
use
statist
analys
variabl
interest
express
absolut
rel
frequenc
student
ttest
independ
sampl
use
comparison
mean
continu
symmetr
distribut
variabl
repeatedmeasur
analysi
varianc
anova
use
analysi
varianc
overal
score
mean
measur
random
patient
includ
analysi
efficaci
intent
treat
analys
level
signific
set
p
random
clinic
trial
perform
use
random
alloc
softwar
simpl
random
two
group
mean
tabl
random
number
gener
simpl
random
spreadsheet
list
random
number
place
seal
envelop
kept
statistician
respons
analys
none
author
access
random
tabl
activ
drug
placebo
capsul
ident
organolept
characterist
standard
label
design
use
group
contain
follow
inform
name
studi
studi
registr
number
hcpa
research
ethic
committe
bottl
numberrandom
number
instruct
use
storag
studi
drug
one
capsul
fixeddos
combin
mg
paracetamol
mg
chlorphenamin
mg
phenylephrin
administ
accord
manufactur
instruct
everi
hour
wake
hour
pm
five
daili
dose
consecut
day
patient
instruct
use
drug
fewer
day
reflect
best
clinic
practic
user
decid
maximum
durat
use
accord
intens
symptom
placebo
one
capsul
administ
everi
hour
wake
hour
pm
five
daili
dose
consecut
day
particip
includ
studi
receiv
bottl
contain
capsul
studi
drug
placebo
depend
group
alloc
one
bottl
contain
tablet
rescu
medic
mg
paracetamol
studi
last
day
includ
three
clinic
visit
two
round
laboratori
test
baselin
addit
medic
histori
physic
examin
particip
underw
laboratori
test
electrocardiogram
ecg
immedi
afterward
randomli
alloc
one
two
group
receiv
studi
drug
placebo
diari
keep
note
symptom
advers
event
rescu
medic
end
treatment
last
day
patient
return
reevalu
second
visit
includ
medic
histori
clinic
physic
examin
ecg
laboratori
test
well
analysi
follow
aspect
symptom
use
predefin
scale
advers
event
durat
symptom
time
return
usual
activ
drug
intak
count
capsul
tablet
use
third
last
followup
visit
took
place
day
end
treatment
follow
paramet
evalu
persist
symptom
accord
predefin
scale
durat
symptom
time
return
usual
activ
advers
event
use
medic
stop
use
studi
drug
group
alloc
disclos
data
collect
enter
studi
databas
doubl
independ
entri
follow
comparison
two
dataset
envelop
contain
random
primari
endpoint
sum
score
common
cold
flulik
syndrom
symptom
evalu
fourpoint
likerttyp
scale
intens
sever
symptom
mild
moder
sever
maximum
minimum
score
measur
zero
respect
scale
use
physician
visit
also
patient
daili
selfevalu
use
studi
diari
particip
rate
symptom
home
administr
studi
drug
placebo
throughout
treatment
period
total
measur
obtain
secondari
endpoint
overal
symptom
durat
time
return
usual
activ
use
rescu
medic
drug
safeti
evalu
occurr
advers
event
detect
clinic
histori
physic
examin
find
abnorm
lab
result
treatment
day
last
dose
medic
seriou
nonseri
advers
event
fulli
document
use
clinic
chart
origin
document
specif
form
addit
advers
event
occur
within
day
treatment
investig
record
compar
group
advers
event
follow
resolut
followup
classifi
write
complet
investig
studi
approv
ethic
committe
graduat
studi
research
group
hospit
de
de
porto
alegr
hcpa
particip
volunt
procedur
studi
start
particip
read
sign
inform
consent
form
approv
hcpa
research
ethic
committe
studi
includ
patient
randomli
distribut
two
group
placebo
treatment
patient
figur
tabl
show
baselin
characterist
studi
sampl
group
homogen
except
weight
greater
treatment
group
mean
time
hour
signific
betweengroup
differ
p
mean
symptom
score
calcul
group
treatment
without
data
loss
patient
attend
visit
mean
overal
symptom
score
placebo
group
treatment
group
demonstr
similar
group
time
point
overal
symptom
score
markedli
reduc
group
placebo
group
treatment
group
separ
comparison
mean
overal
score
symptom
evalu
physician
show
score
lower
treatment
group
trend
toward
statist
signific
p
comparison
overal
score
reduct
induc
treatment
placebo
two
group
reveal
reduct
significantli
greater
treatment
group
p
figur
total
number
day
report
symptom
measur
subject
placebo
treatment
group
respect
mean
sd
number
day
symptom
day
placebo
group
day
activ
treatment
group
p
analysi
symptom
score
curv
group
reveal
curv
separ
second
dose
anova
show
first
dose
interv
figur
correspond
least
hour
treatment
statist
signific
reduct
symptom
score
occur
treatment
group
comparison
placebo
group
p
anova
includ
first
dose
interv
time
correspond
hour
treatment
includ
hour
sleep
also
reveal
reduct
symptom
score
treatment
group
statist
signific
differ
p
evalu
use
rescu
medic
mg
paracetamol
mean
number
tablet
taken
total
number
patient
use
rescu
medic
group
compar
mean
number
tablet
taken
lower
treatment
group
placebo
group
vs
p
greater
percentag
patient
placebo
group
use
rescu
paracetamol
treatment
group
differ
statist
signific
chisquar
test
p
mean
axillari
temperatur
statist
differ
group
differ
axillari
temperatur
valu
overal
incid
patientreport
advers
event
event
placebo
group
treatment
figur
mean
symptom
score
treatment
comparison
mean
overal
score
student
ttest
independ
sampl
mean
score
variat
two
group
student
ttest
independ
sampl
group
statist
signific
betweengroup
differ
p
furthermor
analysi
incid
specif
symptom
group
reveal
statist
signific
differ
distribut
number
advers
event
homogen
two
group
main
advers
event
report
drowsi
n
follow
nausea
n
overal
patient
experienc
type
advers
effect
group
mean
heart
rate
hr
bpm
treatment
group
bpm
placebo
group
mean
hr
bpm
treatment
group
bpm
placebo
group
comparison
hr
variat
treatment
reveal
signific
betweengroup
differ
p
mean
systol
blood
pressur
sbp
mmhg
treatment
group
mmhg
placebo
group
differ
signific
p
mean
sbp
mmhg
treatment
group
mmhg
placebo
group
differ
statist
signific
p
comparison
bp
variat
treatment
reveal
signific
differ
p
laboratori
test
result
show
clinic
relev
chang
relat
studi
variabl
urinalysi
densiti
ph
proteinuria
glycosuria
ketonuria
bilirubin
urobilinogen
haemoglobinuria
nitrit
leukocyt
esteras
fbc
result
significantli
differ
seriou
advers
event
record
studi
patient
withdrew
studi
due
advers
event
reason
exclus
sampl
shown
figur
first
random
doubleblind
clinic
trial
demonstr
efficaci
fixeddos
combin
mg
paracetamol
mg
chlorphenamin
mg
phenylephrin
reduc
flulik
symptom
mean
object
evalu
symptom
investig
subject
report
provid
patient
evalu
rescu
paracetamol
use
dichotom
variabl
show
patient
placebo
group
versu
treatment
group
use
rescu
medic
differ
indic
everi
four
patient
treat
studi
drug
one
take
rescu
paracetamol
nnt
reduct
rate
rescu
medic
use
index
analges
efficaci
demonstr
patient
flulik
symptom
actual
seek
altern
form
relief
medic
take
efficaci
time
freedom
symptom
lower
treatment
group
placebo
group
although
differ
reach
statist
signific
comparison
baselin
final
score
reveal
group
experienc
major
reduct
total
symptom
score
assess
investig
report
patient
result
may
attribut
fact
common
cold
selflimit
diseas
rapid
symptom
reduct
preclud
demonstr
betweengroup
differ
end
treatment
hour
therefor
fact
treatment
group
statist
signific
differ
placebo
group
time
point
support
efficaci
studi
drug
evalu
patientreport
symptom
score
studi
diari
anova
show
statist
signific
reduct
symptom
score
treatment
group
compar
placebo
group
p
differ
point
symptom
score
constant
first
dose
translat
trend
toward
reduct
total
durat
symptom
confirm
larger
studi
find
could
major
impact
popul
given
high
annual
incid
flulik
syndrom
larg
number
user
overthecount
medic
symptomat
relief
symptom
worldwid
dose
symptom
score
low
similar
group
confirm
selflimit
characterist
diseas
made
difficult
patient
assign
score
symptom
accord
studi
protocol
patient
take
medic
either
activ
placebo
dose
correspond
hour
day
explain
reduct
number
case
analysi
dose
analysi
hr
variat
attribut
treatment
reveal
activ
formul
increas
hr
furthermor
treatment
increas
systol
bp
small
betweengroup
differ
variabl
alreadi
detect
baselin
although
signific
patient
treatment
group
higher
baselin
mean
valu
mmhg
differ
may
attribut
random
howev
mean
valu
group
within
normal
limit
baselin
treatment
increas
mean
systol
bp
attribut
treatment
activ
formul
mmhg
therefor
increas
sensit
sympathomimet
agent
respons
treatment
group
intens
placebo
group
absenc
patientor
investigatordetect
effect
cardiovascular
paramet
hr
sbp
suggest
studi
drug
increas
cardiovascular
risk
henc
rct
add
valuabl
safeti
data
particularli
regard
effect
decongest
agent
phenylephrin
blood
pressur
heart
rate
ecg
paramet
limit
studi
must
mention
includ
difficulti
studi
diseas
common
cold
selflimit
combin
multipl
symptom
rapid
rate
resolut
major
patient
symptomfre
day
end
treatment
moreov
patient
low
symptom
score
random
probabl
gener
accept
concept
athom
recoveri
flulik
ill
limit
neg
influenc
identif
sever
diseas
combin
rapid
resolut
symptom
low
symptom
score
reduc
possibl
identifi
betweengroup
differ
reason
statist
signific
differ
found
might
interpret
potenti
clinic
relev
safeti
analysi
reveal
clinic
relev
chang
clinic
laboratori
variabl
two
time
point
evalu
whether
withingroup
betweengroup
activ
vs
placebo
furthermor
statist
signific
betweengroup
differ
treatmentemerg
advers
effect
administr
studi
drug
dose
suggest
packag
insert
efficaci
placebo
symptomat
treatment
common
cold
flulik
ill
studi
drug
also
reduc
frequenc
use
rescu
medic
compar
placebo
safe
placebo
find
suggest
fixeddos
combin
paracetamol
chlorphenamin
phenylephrin
may
effect
safe
altern
treatment
clinic
entiti
studi
fund
manufactur
test
product
research
agreement
includ
reimburs
author
expens
author
declar
manufactur
particip
design
studi
data
collect
statist
plan
analysi
data
evalu
interpret
manuscript
prepar
public
author
contribut
pdp
princip
investig
respons
plan
coordin
studi
statist
analysi
text
edit
mcb
particip
phase
studi
plan
manuscript
write
respons
studi
logist
monitor
prepar
final
version
paper
rvp
prepar
dataset
conduct
data
qualif
evalu
final
result
conduct
statist
analysi
prepar
figur
play
major
role
final
edit
paper
lccf
particip
prepar
implement
logist
studi
includ
data
entri
qualif
crf
review
databas
input
contribut
final
version
paper
ml
particip
prepar
implement
logist
studi
includ
data
entri
qualif
crf
review
databas
input
contribut
final
version
paper
ic
respons
manag
financi
plan
execut
studi
particip
prepar
implement
logist
studi
contribut
final
version
paper
add
particip
prepar
implement
logist
studi
includ
data
entri
qualif
crf
review
databas
input
contribut
final
version
paper
lfc
princip
coinvestig
respons
medic
review
patient
data
input
crf
contribut
final
version
paper
author
read
approv
final
manuscript
